secwatch.observer — SEC 8-K summary
======================================

Issuer:     IMMUNIC, INC. (IMUX)
CIK:        0001280776
Form:       8-K
Filed at:   2026-05-13T11:01:04+00:00
Accession:  0001193805-26-000593
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunic reports Q1 net loss $32.6M; cash $186.6M; Phase 3 MS data by end-2026
-----------------------------------------------------------------------------

- Net loss $32.6M ($1.08/share) vs $25.5M ($2.51/share) YoY; R&D expenses $25.6M.
- Closed $200M private placement (up to $400M) in Feb 2026; cash $186.6M funds into late 2027.
- Appointed Michael Panzara, M.D., as CMO; initiated CEO search with commercial neurology expertise.
- Phase 3 ENSURE RMS top-line data expected by end 2026; NDA submission planned mid-2027.
- Key European patent granted for vidofludimus calcium with potential exclusivity into 2043.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1280776/000119380526000593/0001193805-26-000593-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1280776/000119380526000593/e665461_8k-immunic.htm
  HTML page:      https://secwatch.observer/filing/0001193805-26-000593

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer